

# PRE-MONEY VALUATION (PMV)

This report contains the venture's current estimated pre-money valuation, a snapshot illustration of where the business currently stands with respect to certain investment criteria, the questions from Worthworm's questionnaire, and the account holder's answers to them.





**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



PMV Summary				
Venture Name:	BioLeonhardt	Account Holder:	Howard Leonhardt	
Industry Sector:	Healthcare	Date of Report:	11/17/2017	
Stage of Development:	Established	Desired Funding:	\$500,000	

#### **Pre-Money Valuation Report (PMV)**



This is a valuation bar. The triangle indicates the venture's current estimated PMV, and the bar on which the triangle rests illustrates how much higher or lower the venture's PMV could be based on operational and other risks, as well as the levels of confidence the account holder expressed when answering the questionnaire

#### **VENTURE SNAPSHOT**

These charts illustrate where the venture currently stands with respect to certain investment criteria. The two axes represent the investment criteria, and the green dot shows the venture's current position based on the account holder's answers to the Worthworm questionnaire.

\$21,760,045 | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75




OrthodontiCell.20171117.pdf | 10:00AM | 11/17













#### THE WORTHWORM QUESTIONNAIRE

The estimated PMV calculation in this report started with the account holder answering a guided questionnaire comprised of more than 70 questions focusing on key valuation drivers of his or her business. Those answers were put through an all orithm that used nearly 1,100 analytic parameters and over 4,000 outputs, applied a blend of the most widely respected valuation methods for early stage ventures, and compared the venture to third-party research data about companies at the same maturity level and within the same vertical and geographic region. The result is this credible estimated PMV that entrepreneurs and angel investors may confidently use as a reasonable basis for entering into negotiations.

For your convenience and understanding, a complete list of the questions posed to the account holder and his or her answers are presented below. Please note that for many questions, Worthworm asks the user to state his or her confidence in the accuracy of the answer given. Worthworm then uses those confidence levels to analyze the risks and opportunities associated with the user's venture as modeled.

#### **INDUSTRY + MARKET SIZE**

1) What industry does your product(s)/service(s) concern?

1.1) Sector Healthcare



<b>1.2)</b> Group	Healthcare Devices and Supplies
1.3) Industry	Therapeutic Devices
2) How large is that market?	Over \$1B   Confidence: HI
3) How fast is the market growing annually?	>35%, <=50%   Confidence: HI
<b>4)</b> If successful, what is the maximum share of the market you believe you can capture before exit?	u >75%   Confidence: HI
5) How concentrated are the companies in your target industry/market?	A few large companies
PRODUCT MATURITY	
1) What stage of development is your product at?	Established
2) Do you have paying customers now?	Yes: Trial
2a) If yes, are your sales:	Consistent and growing   Confidence: LOW
<b>2b)</b> If yes, customer feedback is:	Excellent as-is   Confidence: HI
3) How far away are you from a demonstrated ability to deliver your product(s)/service(s) reliably at scale and a competitive cost?	Can deliver at scale now   Confidence: HI
COMPETITIVE POSITION	
1) Does your product(s)/service(s) make something possible that wasn't possible before?	Yes   Confidence: HI
2) Has something changed in recent years that made your product(s)/service(s) possible, whereas previously it was not?	Yes   Confidence: HI

Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

\$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

3) Do other companies currently offer competing products/services?	No   Confidence: HI
<b>3g)</b> If your product(s)/service(s) is successful, what prevents other companies from launching competing products/services?	
<b>3g.1)</b> Patents	Yes   Confidence: HI
3g.2) Proprietary technologies	Yes   Confidence: HI
3g.3) Licenses or contracts	Yes   Confidence: HI
3g.4) First to market	Yes   Confidence: HI
3g.5) First to achieve scale	Yes   Confidence: HI
SALES	THE REPORT OF THE PERSON OF TH
1) How will prospective customers learn about your product(s)/service(s)?	
1.1) Direct Sales Force	Yes
1.1a) What is the current state of development?	Proven and scalable
1.2) Indirect Sales	Yes
1.2a) What is the current state of development?	Proven and scalable
1.3) Sales Partners and Their Channels	Yes
1.3a) What is the current state of development?	Proven and scalable

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



<b>1.4)</b> Direct Marketing (Infomercials, Online Sales, Catalogue, Direct Mail, etc.)	Yes
1.4a) What is the current state of development?	Proven and scalable
2) Does your product(s)/service(s) meet an acknowledged need or enable something new?	Acknowledged need   Confidence: HI
3) Will buyers of your product(s)/service(s) have to change their daily habits to use your product/service, or incur significant cost to switch?	No   Confidence: HI
4) Do you rely on taking market share from well-entrenched companies?	Yes   Confidence: HI
MANAGEMENT	SEL
1) Is there a CEO or president in place?	In place
1a) Will the CEO or president serve full time or part time?	Full time
<b>1b)</b> Does the CEO or president have prior experience in that role?	Yes
1c) What is the CEO's or president's experience in your company's market?	>=10 years
2) Is there a sales executive in place?	In place
2a) Does the sales executive have prior experience in that role?	Yes
2b) What is the sales executive's prior leadership experience?	>=10 years
2c) What is the sales executive's experience in your company's market?	>=10 years
3) Is there a marketing executive in place?	In place

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



3a) Does the marketing executive have prior experience in that role?	Yes
<b>3b)</b> What is the marketing executive's prior leadership experience?	>=10 years
<b>3c)</b> What is the marketing executive's experience in your company's market?	>=10 years
4) Is there a customer service executive in place?	In place
4a) Does the customer service executive have prior experience in that role?	Yes
4b) What is the customer service executive's prior leadership experience?	>=10 years
<b>4c)</b> What is the customer service executive's experience in your company's market?	>=10 years
5) Is there an engineering executive/product development executive/CTO in place?	In place
5a) Does the technical executive have prior experience in that role?	Yes
<b>5b)</b> What is the technical executive's prior leadership experience?	>=10 years
<b>5c)</b> What is the technical executive's experience in your company's market?	>=10 years
6) Is there an operations executive in place?	In place
6a) Does the operations executive have prior experience in that role?	Yes
<b>6b)</b> What is the operation executive's prior leadership experience?	>=10 years
6c) What is the operations executive's experience in your company's market?	>=10 years

# Worthworm.com BioLeonhardt | Howard Leonhardt | OrthodontiCell.20171117.pdf | 10:00AM | 11/17

\$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

# **\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

**PMV REPORT** 

7) Is there a financial executive in place?	In place
7a) Does the financial executive have prior experience in that role?	Yes
<b>7b)</b> What is the financial executive's prior leadership experience?	>=10 years
7c) What is the financial executive's experience in your company's market?	>=10 years
FUTURE ROUNDS	
1) How many rounds of capital do you expect to require after completing the current round?	1   Confidence: HI
2) How much dilution do you expect in each of these future rounds?	
2.1) Dilution in Future Round 1	>15%, <=35%   Confidence: HI
INVESTOR EXIT	
1) If your company is successful, how do you expect investors to exit from their investment	Acquisition   Confidence: HI
2) If you think your price/sales exit multiplier should differ from 1.5, please select your multiplier from the drop-down menu.	2.75
S JE ZO S JE ZO JE JE JE ZO JE	
RISK FACTORS	
1) For each of the following, check "Yes" if you consider it to be a significant risk to your success. Check "No" if you don't consider it to be a significant risk to your success.	
1.1) Market size and growth	No
1.2) Building the management team	No No

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



1.3) Product(s)/service(s) development	No
1.4) Competition	No chart of the state of the st
1.5) Intellectual property	No
1.6) Customer acquisition	No said the
1.7) Legal Issues such as Regulatory Approvals and Product/Brand Liability	No
1.8) Product(s)/service(s) delivery	No. The second s
1.9) Key hires	No
1.10) Acquiring key resources (not including people)	No.
1.11) Margin / profitability of business	No
FUNDING	
1) What is your current monthly cash burn?	< \$25,000
2) Do you have positive cash flow from operations?	No
2a) In which round do you expect to achieve positive cash flow?	Future Round 1   Confidence: HI
3) Excluding the founders'/company formation round, how many rounds of funding preceded the current round?	2
3a) How much was raised in each of the rounds preceding the current round?	

# \$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

# **PMV REPORT**

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



<b>3a.1)</b> How much was raised in round 1 (the first round after the Founder's Round)?	500,000.00
3a.2) How much was raised in round 2?	900,000.00
<b>3b)</b> What was the pre-money valuation sustained in each of the rounds preceding the current round?	
<b>3b.1)</b> What was the pre-money valuation in round 1 (the first round after the Founder's Round)?	2,300,000.00
<b>3b.2)</b> What was the pre-money valuation in round 2?	7,000,000.00
<b>4)</b> How many shares of stock or membership units were issued to the founders in the Founder's Round? (For LLCs and other companies for which no shares are issued, please enter the percentage as the number of shares, e.g., 80 shares for 80%).	2,300,000.00
<b>5)</b> How many shares of stock or membership units were initially reserved for employees? (For LLCs and other companies for which no shares are issued, please enter the percentage as the number of shares, e.g., 80 shares for 80%).	460,000.00
6) How much cash, if any, did the founders invest in the company during the Founder's Round?	300,000.00
7) How much cash, if any, will employees be required to invest in exchange for ownership assigned during the Founder's Round?	0.00
8) How much investment are you seeking to raise in this current round?	500,000.00
9) If this funding is secured, how long do you expect that funding to support your cash needs?	More than 18 Months   Confidence: HI
10) How much do you intend to raise in each of the rounds following the current round?	
10.1) What is the amount to be raised in future round 1?	1,000,000.00
11) To project the pre-money valuation for each round following the current	AT ST ST ST ST ST ST ST ST ST

**11)** To project the pre-money valuation for each round following the current round, enter a multiplier to be applied to each future round.

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



11.1) What is the multiplier for future round 1?

3

#### **ABOUT WORTHWORM**

As a Worthworm subscriber, the account holder may invite a number of people (i.e., colleagues, business advisors, and prospective angel investors, etc.) to "seats" from which to view, edit, and/or participate in modeling a venture. The number of collaborator seats available to an account holder is dependent depends upon his or her subscription level. If you're interested in collaborating on or analyzing this venture, we encourage you to ask the account holder for an invitation to collaborate so you can engage in what-if exercises, explore strategies and tactics, actions, and consider alternative answers to the questions Worthworm poses to jointly derive a scenario that you and the account holder can agree fairly and accurately represents and values

If you're not currently a subscriber, please visit www.worthworm.com to join our community of entrepreneurs, angel investors, and professionals who rely on Worthworm to create a stronger, more credible starting point for their venture negotiations.



Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

#### LEGAL

**DISCLAIMER**: Integrus Analytic Systems, LLC ("IAS"), an Arizona limited liability company and the creator of Worthworm™, expresses no opinion whatsoever on the investment quality or worthiness of any venture that uses the Worthworm™ site and technology, nor does IAS express any opinion whatsoever on the reasonableness or accuracy of the data a user inputs to Worthworm™ that serve as the basis for the computations and analyses Worthworm™ performs. Furthermore, IAS offers no assurance whatsoever that any venture that uses the Worthworm™ site and technology will achieve any or all of the assumptions represented in the form of a user's inputs to Worthworm™, and IAS offers no assurance whatsoever that ventures using the Worthworm™ site and technology will achieve any level of market success or provide any return whatsoever to its investor(s).

IAS strongly encourages prospective investors to perform thorough due diligence on any venture that uses the Worthworm™ site and technology, seeking outside experts including accountants and legal counsel as such prospective investors deem necessary in performing said due diligence.

IAS is neither a registered broker/dealer nor a registered investment adviser; consequently, IAS does not perform any services that would require such licensing nor accept compensation related to such services.

IAS offers no assurance whatsoever that the pre-money valuation its Worthworm™ application computes for any given venture is accurate; rather, IAS limits its commitment to users to provide rigorously calculated pre-money valuations and analyses based upon widely accepted valuation methods for early stage companies and other information, including proprietary algorithms, to serve as a basis for negotiations between parties that may or may not result in an investment in a venture at or near the pre-money valuation computed using Worthworm™'s technology. Similarly, IAS offers no assurance whatsoever that a venture's pre-money valuation now or in the future would rise or fall if a venture's management were to take actions to reduce uncertainty and/or capitalize upon an opportunity(ies) as each may be suggested in Worthworm™ analyses. IAS acknowledges that market conditions frequently change and that it is not in a position to accurately predict the nature or timing of such market changes, and that in the event of such market changes, a venture's pre-money valuation could substantially change.

Use of Worthworm<sup>™</sup> in any fashion and for any purpose shall be at user's sole risk. To the fullest extent permitted by law, IAS, its officers, members, directors, employees, and agents disclaim all warranties, express or implied, in connection with Worthworm<sup>™</sup> and the use thereof. IAS assumes no liability or responsibility for any (i) errors, mistakes, or inaccuracies of website content, (ii) personal injury or damage, of any nature whatsoever, resulting from access to and use of Worthworm<sup>™</sup>, (iii) any bugs, viruses, Trojan horses, or the like which may be transmitted to or through the Worthworm<sup>™</sup> website by any third party, and/or (iv) any errors or omissions in any content or for any loss or damage of any kind incurred as a result of the use of any content posted, emailed, transmitted, or otherwise made available via Worthworm<sup>™</sup>.



### **SNAPSHOT REPORT**

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

COMMENTS:

OrthdontiCell Product Is Nearly Ready to Go To Market

#### **PMV VALUATION**



#### What Does The Valuation Bar Mean?

The valuation bar illustrates how much higher or lower your venture's estimated

pre-money valuation could be based on market risk and the level of confidence


you expressed in your answers to Worthworm's™ questionnaire.














# **INPUTS COMPARISON REPORT**

\$21,760,045 | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



Input parameters should be provided to download report to PDF



# **CAPITALIZATION (CAP) TABLE REPORT**



**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

#### **HISTORIC ROUND 1**

	Initial Ownership	Historic	Round 1
FOUNDERS   SHAREHOLDERS	Percent Owned	Percent Owned	Value
Founders	83.33%	68.45%	\$2,300,000
Reserved for Employees	16.67%	13.69%	\$460,000
Historic Round 1 Investors	0.00%	17.86%	\$600,000
	100.00%	100.00%	\$3,360,000

#### HISTORIC ROUND 2

	Initial Ownership	Historic Ro	ound 2
FOUNDERS   SHAREHOLDERS	Percent Owned	Percent Owned	Value
Founders	83.33%	60.65%	\$2,300,000
Reserved for Employees	16.67%	12.13%	\$460,000
Historic Round 1 Investors	0.00%	15.82%	\$600,000
Historic Round 2 Investors	0.00%	11.39%	\$432,000
	100.00%	100.00%	\$3,792,000

#### **CURRENT ROUND**

	Initial Ownership	Current Round	
FOUNDERS   SHAREHOLDERS	Percent Owned	Percent Owned	Value
Founders	83.33%	59.29%	\$2,300,000
Reserved for Employees	16.67%	11.86%	\$460,000
Historic Round 1 Investors	0.00%	15.47%	\$600,000
Historic Round 2 Investors	0.00%	11.14%	\$432,000
Current Round Investors	0.00%	2.25%	\$87,132
	100.00%	100.00%	\$3,879,132

www.worthworm.com

# **CAPITALIZATION (CAP) TABLE REPORT**

Worthworm.com

BioLeonhardt | Howard Leonhardt |
OrthodontiCell.20171117.pdf | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

#### **FUTURE ROUND 4**


	Initial Ownership	Future Rou	ınd 4
FOUNDERS   SHAREHOLDERS	Percent Owned	Percent Owned	Value
Founders	83.33%	58.40%	\$2,300,000
Reserved for Employees	16.67%	11.68%	\$460,000
Historic Round 1 Investors	0.00%	15.23%	\$600,000
Historic Round 2 Investors	0.00%	10.97%	\$432,000
Current Round Investors	0.00%	2.21%	\$87,132
Future Round 4 Investors	0.00%	1.51%	\$59,423

# **EQUITY DILUTION REPORT**

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



**DILUTION CHART** 



# RETURN ON INVESTMENT (ROI) REPORT

Worthworm.com

BioLeonhardt | Howard Leonhardt |
OrthodontiCell.20171117.pdf | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

#### **EXIT PROJECTION**


	Owner	rship Percentage		
SHAREHOLDERS   FOUNDERS	Amount Invested	Exit Percentage Share	of Exit Proceeds	ROI
Founders	\$300,000	58.40%	\$783,400,175	261133.39%
Reserved for Employees	\$0	11.68%	\$156,680,035	0.00%
Historic Round 1 Investors	\$500,000	15.23%	\$204,365,263	40873.05%
Historic Round 2 Investors	\$900,000	10.97%	\$147,142,989	16349.22%
Current Round Investors	\$500,000	2.21%	\$29,677,982	5935.60%
Future Round 4 Investors	\$1,000,000	1.51%	\$20,239,946	2023.99%

#### **Estimated Exit Value**



**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75





Impact of whether company has to take share from entrenched competitors



























Worthworm.com

BioLeonhardt | Howard Leonhardt |



#### **RISKS + OPPORTUNITIES TOOL** worthworm.com **\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75 BioLeonhardt | Howard Leonhardt | OrthodontiCell.20171117.pdf | 10:00AM | 11/17 RESOURCE **REQUIREMENTS** Low **Base** High **Opportunity** 17% 16% 16% 17% 17% 17% 17% 17% 15%-16%--17% 17% 17% 17% 16% -17% 17% 17% 16% 17% 17% 16% 17% Impact of risk factor for hiring Impact of risk factor for profitability Impact of risk factor for resource acquisition Impact of number of additional financing rounds required Impact of how customers learn about product Impact of ability to deliver product at scale PRODUCT MATURITY High **Opportunity** Low **Base** 13% 14% 20% 20% 22% -22% 22% 22%-23%-21%-20% 20% 22% 21% 22% 21%-22%-23%-20%

Impact of risk factor for product development

Impact of whether sales are consistent

Impact of customer feedback

Impact of product maturity

Impact of having customers







worthworm.com


BioLeonhardt | Howard Leonhardt |

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



Worthworm.com

BioLeonhardt | Howard Leonhardt |



# \$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

# **NEXT STEPS TOOL**

Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

#### **COMBINED RISK + VALUE**

VALUATION DRIVERS NEW VALUATION DELTA vs. EXISTING

VALUATION DRIVERS		NEW VALUATION	<u> </u>	DELTA VS. EXISTING			5. 2
FIRST STEP	SECOND STEP	MIN	VALUE	MAX	ΔΜΙΝ	ΔVALUE	ΔΜΑΧ
1) Sales capability	Product Maturity	\$22,299,511	\$22,705,424	\$23,142,280	\$920,763	\$945,379	\$1,315,669
2) Product maturity	Sales Capability	\$22,299,511	\$22,705,424	\$23,142,280	\$920,763	\$945,379	\$1,315,669
3) Product maturity	Resource Requirements	\$21,856,572	\$22,576,508	\$23,370,185	\$477,824	\$816,463	\$1,543,574
4) Resource requirements	Product Maturity	\$21,856,572	\$22,576,508	\$23,370,185	\$477,824	\$816,463	\$1,543,574
5) Product maturity	Delivery Capability	\$22,020,682	\$22,533,537	\$23,086,615	\$641,933	\$773,492	\$1,260,004
6) Delivery capability	Product Maturity	\$22,020,682	\$22,533,537	\$23,086,615	\$641,933	\$773,492	\$1,260,004
7) Sales capability (R)	Product Maturity	\$22,059,270	\$22,447,593	\$22,860,405	\$680,521	\$687,548	\$1,033,794
8) Product differentiation (R)	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
9) Team completeness (R)	Product Maturity	\$22,231,243	\$22,447,593	\$22,678,383	\$852,495	\$687,548	\$851,772
10) Exit multiple (R)	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
11) Delivery capability (R)	Product Maturity	\$22,075,385	\$22,447,593	\$22,845,672	\$696,636	\$687,548	\$1,019,061
12) Team completeness	Product Maturity	\$22,231,243	\$22,447,593	\$22,678,383	\$852,495	\$687,548	\$851,772
13) Team strength (R)	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
14) Product maturity	Team Strength (R)	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
15) Product maturity	Market Size & Growth (R)	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
16) Product maturity	Competition & Barriers (R)	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
17) Product maturity	Team Completeness	\$22,231,243	\$22,447,593	\$22,678,383	\$852,495	\$687,548	\$851,772
18) Product maturity	Product Differentiation (R)	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395

# **NEXT STEPS TOOL**

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75



19) Product maturity	Exit Multiple (R)	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
20) Product maturity	Sales Capability (R)	\$22,059,270	\$22,447,593	\$22,860,405	\$680,521	\$687,548	\$1,033,794

### **RISK**

VALUATION DRIVERS	of the second	NEW VALUATIO	ON	8 5	DELTA vs. EXIS	TING	w RIFE (
FIRST STEP	SECOND STEP	MIN	VALUE	MAX	ΔΜΙΝ	ΔVALUE	ΔΜΑΧ
1) Sales capability (R)	Competition & Barriers (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
2) Sales capability (R)	Product Differentiation (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
3) Sales capability (R)	Product Maturity (R)	\$21,369,234	\$21,760,045	\$22,184,423	-\$9,514	\$0	\$357,812
4) Sales capability (R)	Delivery Capability (R)	\$21,363,458	\$21,760,045	\$22,178,111	-\$15,290	\$0	\$351,500
5) Sales capability (R)	Projected Dilution (R)	\$21,519,317	\$21,760,045	\$21,993,633	\$140,568	\$0	\$167,022
6) Sales capability (R)	Market Share (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
7) Sales capability (R)	Team Completeness (R)	\$21,519,317	\$21,760,045	\$22,010,822	\$140,568	\$0	\$184,211
8) Sales capability (R)	Resource Requirements (R)	\$21,225,060	\$21,760,045	\$22,333,982	-\$153,689	\$0	\$507,371
9) Sales capability (R)	Team Strength (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
10) Sales capability (R)	Market Size & Growth (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
11) Sales capability (R)	Exit Multiple (R)	\$21,553,694	\$21,760,045	\$21,976,444	\$174,946	\$0	\$149,833
12) Product differentiation (R)	Product Maturity (R)	\$21,575,585	\$21,760,045	\$21,968,024	\$196,837	\$0	\$141,413
13) Product differentiation (R)	Market Size & Growth (R)	\$21,760,045	\$21,760,045	\$21,760,045	\$381,297	\$0	-\$66,566
14) Product differentiation (R)	Team Completeness (R)	\$21,725,668	\$21,760,045	\$21,794,423	\$346,919	\$0	-\$32,189
15) Product differentiation (R)	Exit Multiple (R)	\$21,760,045	\$21,760,045	\$21,760,045	\$381,297	\$0	-\$66,566

# \$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

# **NEXT STEPS TOOL**

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

Worthworm.com

BioLeonhardt | Howard Leonhardt |
OrthodontiCell.20171117.pdf | 10:00AM | 11/17

						4	V 0 4
16) Product differentiation (R)	Competition & Barriers (R)	\$21,760,045	\$21,760,045	\$21,760,045	\$381,297	\$0	-\$66,566
17) Product differentiation (R)	Delivery Capability (R)	\$21,569,809	\$21,760,045	\$21,961,712	\$191,061	\$0	\$135,101
18) Product differentiation (R)	Projected Dilution (R)	\$21,725,668	\$21,760,045	\$21,777,234	\$346,919	\$0	-\$49,377
19) Product differentiation (R)	Team Strength (R)	\$21,760,045	\$21,760,045	\$21,760,045	\$381,297	\$0	-\$66,566
20) Product differentiation (R)	Market Share (R)	\$21,760,045	\$21,760,045	\$21,760,045	\$381,297	\$0	-\$66,566

#### **VALUE**

	VALUATION DRIVERS		NEW VALUATIO	ON	DELTA vs. EXISTING			31,10	
É	FIRST STEP	SECOND STEP	MIN	VALUE	MAX	ΔΜΙΝ	ΔVALUE	ΔΜΑΧ	
	1) Sales capability	Product Maturity	\$22,299,511	\$22,705,424	\$23,142,280	\$920,763	\$945,379	\$1,315,669	
	2) Product maturity	Sales Capability	\$22,299,511	\$22,705,424	\$23,142,280	\$920,763	\$945,379	\$1,315,669	
	3) Product maturity	Resource Requirements	\$21,856,572	\$22,576,508	\$23,370,185	\$477,824	\$816,463	\$1,543,574	
	4) Resource requirements	Product Maturity	\$21,856,572	\$22,576,508	\$23,370,185	\$477,824	\$816,463	\$1,543,574	
	5) Product maturity	Delivery Capability	\$22,020,682	\$22,533,537	\$23,086,615	\$641,933	\$773,492	\$1,260,004	
	6) Delivery capability	Product Maturity	\$22,020,682	\$22,533,537	\$23,086,615	\$641,933	\$773,492	\$1,260,004	
	7) Team completeness	Product Maturity	\$22,231,243	\$22,447,593	\$22,678,383	\$852,495	\$687,548	\$851,772	
	8) Product maturity	Team Completeness	\$22,231,243	\$22,447,593	\$22,678,383	\$852,495	\$687,548	\$851,772	
8	9) Product maturity	Product Differentiation	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395	
0	10) Product maturity	Competition & Barriers	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395	
Ó	11) Product maturity	Team Strength	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395	
Ç.Ò	12) Competition & barriers	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395	

www.worthworm.com

# **NEXT STEPS TOOL**

6, 6

Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

					V // // //	6.7 .	~~ I I
13) Product differentiation	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
14) Team strength	Product Maturity	\$22,265,621	\$22,447,593	\$22,644,006	\$886,872	\$687,548	\$817,395
15) Sales capability	Resource Requirements	\$21,384,888	\$22,146,791	\$22,984,499	\$6,139	\$386,746	\$1,157,888
16) Resource requirements	Sales Capability	\$21,384,888	\$22,146,791	\$22,984,499	\$6,139	\$386,746	\$1,157,888
17) Sales capability	Delivery Capability	\$21,548,997	\$22,103,819	\$22,700,928	\$170,248	\$343,774	\$874,317
18) Delivery capability	Sales Capability	\$21,548,997	\$22,103,819	\$22,700,928	\$170,248	\$343,774	\$874,317
19) Team completeness	Sales Capability	\$21,759,558	\$22,017,876	\$22,292,697	\$380,810	\$257,831	\$466,086
20) Sales capability	Product Differentiation	\$21,793,936	\$22,017,876	\$22,258,319	\$415,187	\$257,831	\$431,708

# **SELF-DIRECTED NEXT STEPS TOOL**

Worthworm.com

BioLeonhardt | Howard Leonhardt |

OrthodontiCell.20171117.pdf | 10:00AM | 11/17

**\$21,760,045** | P|S Multiple per Worthworm - 1.5000, P|S Multiple per User - 2.75

**DISTRIBUTION TREE** 

#### **VALUATION TREE**

ORIGINAL VALUATION



Input parameters should be provided to download report to PDF

www.worthworm.com

\$21,760,045 | BioLeonhardt | Howard Leonhardt | 10:00AM | 11/17

PAGE 36 OF 36